Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054535 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00054535: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00054535 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054535, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant fowlpox-tyrosinase vaccine
- BIOLOGICAL vaccinia-tyrosinase vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054535
The ClinicalTrials.gov registry entry for NCT00054535 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which aldesleukin is the first listed.
NCT00054535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054535 about?
NCT00054535 is a clinical study titled "Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who hav...
What is the current status of trial NCT00054535?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00054535?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant fowlpox-tyrosinase vaccine (BIOLOGICAL), vaccinia-tyrosinase vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00054535?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.